Literature DB >> 24818880

Engineered, self-assembled near-infrared photothermal agents for combined tumor immunotherapy and chemo-photothermal therapy.

Yu Tao1, Enguo Ju1, Zhen Liu1, Kai Dong1, Jinsong Ren2, Xiaogang Qu3.   

Abstract

New combination therapy strategy, which takes the advantages of co-delivery two or more therapeutic agents in one nanocarrier platform, has been widely used in the clinic and achieved immense popularity in cancer treatment. Here, we have rationally developed a multifunctional platform using a self-assembly strategy to incorporate materials with specific functions of chemotherapeutics, hyperthermia, and especially immunotherapy, which can collectively contribute to the effective cancer treatment. We design the immunomodulatory CpG ODNs based platform that is conjugated with NIR-responsive gold nanorods and doxorubicin for cancer therapy. The gold nanorods can be applied as the nanocarrier to simultaneously address the three kinds of treatments, which lead to a significant benefit relative to the use of each method alone. Both in vitro and in vivo assays reveal that this engineered vehicle exhibits significant antitumor efficacy. Our studies provide strong evidence that the AuNRs-CpG-Dox conjugates can be utilized as efficient antitumor agents.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Combination therapy; CpG ODNs; Hyperthermia; Immunotherapy

Mesh:

Substances:

Year:  2014        PMID: 24818880     DOI: 10.1016/j.biomaterials.2014.04.073

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  27 in total

1.  Nanoparticle Design Strategies for Effective Cancer Immunotherapy.

Authors:  Praveena Velpurisiva; Aniket Gad; Brandon Piel; Rahul Jadia; Prakash Rai
Journal:  J Biomed (Syd)       Date:  2017

2.  BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy.

Authors:  Benqing Zhou; Jun Song; Meng Wang; Xin Wang; Jielin Wang; Eric W Howard; Feifan Zhou; Junle Qu; Wei R Chen
Journal:  Nanoscale       Date:  2018-11-29       Impact factor: 7.790

3.  Metallic Nanoparticles for Cancer Immunotherapy.

Authors:  Emily Reiser Evans; Pallavi Bugga; Vishwaratn Asthana; Rebekah Drezek
Journal:  Mater Today (Kidlington)       Date:  2017-12-14       Impact factor: 31.041

4.  Vitamin E-rich Nanoemulsion Enhances the Antitumor Efficacy of Low-Dose Paclitaxel by Driving Th1 Immune Response.

Authors:  Jun Ye; Wujun Dong; Yanfang Yang; Huazhen Hao; Hengfeng Liao; Bangyuan Wang; Xue Han; Yiqun Jin; Xuejun Xia; Yuling Liu
Journal:  Pharm Res       Date:  2017-03-21       Impact factor: 4.200

Review 5.  Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment.

Authors:  Rachel S Riley; Emily S Day
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-03

6.  Light: A Magical Tool for Controlled Drug Delivery.

Authors:  Yu Tao; Hon Fai Chan; Bingyang Shi; Mingqiang Li; Kam W Leong
Journal:  Adv Funct Mater       Date:  2020-09-09       Impact factor: 18.808

Review 7.  Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.

Authors:  Xiaopin Duan; Christina Chan; Wenbin Lin
Journal:  Angew Chem Int Ed Engl       Date:  2018-11-15       Impact factor: 15.336

Review 8.  Immunomodulatory Nanosystems.

Authors:  Xiangru Feng; Weiguo Xu; Zhongmin Li; Wantong Song; Jianxun Ding; Xuesi Chen
Journal:  Adv Sci (Weinh)       Date:  2019-06-21       Impact factor: 16.806

9.  Dual-Color Plasmonic Nanosensor for Radiation Dosimetry.

Authors:  Yu Tao; Mingqiang Li; Xiangyu Liu; Kam W Leong; Jean Gautier; Shan Zha
Journal:  ACS Appl Mater Interfaces       Date:  2020-05-07       Impact factor: 9.229

10.  Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities.

Authors:  Guanyou Lin; Richard A Revia; Miqin Zhang
Journal:  Adv Funct Mater       Date:  2020-10-13       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.